Trial Profile
Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 11 Oct 2016 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Results of a post-hoc biomarker analysis published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 09 Nov 2015 Subgroup analysis results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015